Core Viewpoint - Hansoh Pharmaceutical plans to raise HKD 3.9 billion through a placement, marking its third refinancing since its listing, with its stock price currently at approximately 80% of its historical high [2] Group 1: Financing Activities - Since the beginning of 2025, over 20 innovative pharmaceutical companies listed in Hong Kong have engaged in refinancing, significantly surpassing the same period last year, with total refinancing exceeding HKD 34 billion [2][4] - WuXi AppTec raised nearly HKD 7.7 billion through a share placement, making it the highest fundraising company in this round of refinancing [5] - Innovent Biologics raised approximately HKD 4.3 billion through the placement of 55 million new shares, with 90% of the funds allocated for global R&D and facility layout [5] Group 2: Stock Performance and Market Trends - The stock prices of many innovative pharmaceutical companies have doubled since the beginning of the year, indicating a market recovery [2] - Innovent Biologics' stock price has increased over 2.5 times since the start of the year, reflecting strong market interest [10] Group 3: Shareholder Actions - Some founders and major shareholders are taking the opportunity to reduce their holdings and cash out, despite the ongoing fundraising activities [4][10] - Notable reductions include Temasek's divestment of over HKD 2.4 billion from Innovent Biologics and significant sales by other major shareholders in various companies [10][11] Group 4: Alternative Financing Methods - Several companies are utilizing "old-for-new" financing methods, where founders sell their old shares to new investors and use the cash to subscribe to new shares, making it more attractive for investors [7][8] - Companies like Aisheng Pharmaceutical and others have successfully raised funds through this method, indicating a trend in the market [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's drug commercialization is in line with expectations, and the potential for clinical advancement has significantly increased [1] - The core product, Orebate, has shown impressive sales growth, with a year-on-year increase of 92.4% to 217 million yuan in the first half of 2025, and is expected to double by the end of the year [7] - The company has successfully launched another product, Lisatoclax, which received conditional approval for marketing, indicating strong commercialization progress [7] - The company has a robust cash reserve of over 3 billion yuan, sufficient to support ongoing pipeline development [7] - Revenue forecasts for 2025-2027 have been revised upwards due to the anticipated sales growth of Orebate and Lisatoclax [7] Financial Summary - Total revenue for 2023 is projected at 225.09 million yuan, with significant growth expected in subsequent years, reaching 3,265.89 million yuan by 2026 [1] - The net profit for 2023 is expected to be a loss of 925.64 million yuan, with a forecasted recovery to a profit of 1,058.67 million yuan by 2026 [1] - The earnings per share (EPS) is projected to improve from a loss of 2.49 yuan in 2023 to a profit of 2.85 yuan in 2026 [1] - The company’s cash and cash equivalents are expected to reach 1,105.83 million yuan by 2025, supporting its operational needs [8]

Major Events - Alibaba-W (09988) plans to spin off its Zhaima business and list it independently on the Hong Kong Stock Exchange [1] - WanGuo Gold Group (03939) intends to conduct a placement of 22.5 million shares at a discount of approximately 7.00%, raising about HKD 722 million [1] - Boyaa Interactive (00434) plans to place up to 63.51 million shares at a discount of approximately 8.19%, aiming to raise about HKD 436 million [1] - China Petroleum & Chemical Corporation (00386) plans to repurchase A-shares with an investment of between RMB 500 million and RMB 1 billion [1] Operating Performance - AIA Group (01299) reported a 14% year-on-year increase in business value to USD 2.838 billion and proposed an interim dividend of HKD 0.49 per share [1] - Kuaishou-W (01024) reported a profit attributable to equity holders of RMB 4.922 billion for Q2, a year-on-year increase of 23.7% [1] - Bilibili-W (09626) reported a net profit attributable to shareholders of RMB 219 million for Q2, returning to profitability [1] - China Power (02380) reported a profit attributable to shareholders of RMB 2.587 billion, a year-on-year increase of 0.65% [1] - Ascentage Pharma-B (06855) reported revenue of RMB 234 million, with sales of its product Olverembatinib in China increasing by 93% year-on-year [1] - AAC Technologies (02018) reported a profit attributable to shareholders of RMB 876 million, a year-on-year increase of 63.1% [1] - Fourth Paradigm (06682) reported a gross profit of RMB 990 million, a year-on-year increase of 25.38% [1] - East Asia Bank (00023) reported a profit attributable to shareholders of HKD 2.407 billion, a year-on-year increase of 14.02% [1] - Tuhu-W (09690) reported an adjusted net profit of RMB 410 million, a year-on-year increase of 14.6% [1] - Highway Electronics (01415) reported a net profit attributable to equity shareholders of approximately USD 67.4 million, a year-on-year increase of about 3.2 times [1] - SOTY Technology (02498) reported a gross profit increase of 106.12% year-on-year to RMB 203 million [1] - China Communications Services (00552) reported a profit attributable to shareholders of RMB 2.129 billion, a year-on-year increase of 0.18% [1] - Hengan International (01044) reported a profit attributable to shareholders of RMB 1.373 billion, a year-on-year decrease of 2.6% [1] - China Resources Power (00836) reported a profit attributable to shareholders of HKD 7.872 billion, a year-on-year decrease of 15.92% [1] - Miniso Group (09896) reported a profit attributable to shareholders of RMB 906 million, a year-on-year decrease of 22.6% [1] - BOC Aviation (02588) reported a net profit of USD 342 million, a year-on-year decrease of 26% [2] - Sinopec (00386) reported a net profit of RMB 21.483 billion, a year-on-year decrease of 39.8% [2] - Tiansheng Pharmaceutical-B (02137) reported a loss attributable to shareholders of approximately RMB 148 million, a year-on-year decrease of 47.22% [2]

Core Insights - The core viewpoint of the article highlights the significant growth in sales of Ascentage Pharma's key product, Nairik (Orebatinib), which saw a 93% increase in revenue to RMB 217 million, driven by expanded coverage in the national medical insurance directory [1][3] - The company is transitioning from a research-focused biotech firm to a fully commercialized innovative pharmaceutical enterprise, with a strong emphasis on the commercialization of its innovative drugs [6][9] Financial Performance - As of June 30, the company reported cash and bank deposits of RMB 1.661 billion, a year-on-year increase of 31.7%, primarily due to net proceeds of RMB 970 million from its IPO in January 2025 [1] - The sales and distribution expenses increased by RMB 48.2 million, a 53.7% year-on-year rise to RMB 138 million, attributed to the commercialization of Nairik and preparations for the launch of another product, Lisengto [7] Product Development - Nairik is the first approved third-generation BCR-ABL inhibitor in China, with its sales revenue growing from RMB 113 million to RMB 217 million, following its inclusion in the national medical insurance directory [3][4] - Lisengto (Lisatrag) was approved for use in July 2025, becoming China's first domestically developed Bcl-2 inhibitor, which is expected to further enhance the company's product portfolio [4][6] Market Strategy - The company aims to balance high R&D investments with commercial output, with expectations of achieving breakeven by 2027 through the sales profits of its products [7] - The company has engaged in overseas licensing agreements, which have positively impacted cash flow and helped address short-term commercialization needs [8][9] Competitive Landscape - The company faces challenges in a competitive market, particularly in the context of similar products, but its innovative drugs have shown differentiated advantages in clinical data [5][6] - The ongoing support from national medical insurance for innovative products is expected to enhance market recognition for companies with strong commercialization capabilities [9]

Group 1 - The company reported a revenue of 234 million yuan for the first half of 2025, with its core product, Nairike, generating sales of 217 million yuan, representing a 93% year-on-year increase, primarily due to all approved indications being included in medical insurance [1] - The company has over 3 billion yuan in cash, indicating improved cash flow and strong liquidity [1] - The company’s other core product, Lisengmo, was approved for market launch by the National Medical Products Administration (NMPA) in July 2025, marking the beginning of a dual-engine growth phase for the company [1] Group 2 - Lisengmo, in combination with Azacitidine (AZA), received approval to conduct a global Phase III clinical trial (GLORA-4) from both the FDA and EMA, which is currently underway with patient enrollment [2] - The GLORA-4 study has already completed the first patient enrollment in China and Europe, facilitating the clinical development and registration process for Lisengmo in myelodysplastic syndromes (MDS) [2] Group 3 - The company has signed cooperation agreements with major pharmaceutical distribution companies to advance the commercialization of Lisengmo, achieving rapid product rollout in over 30 cities and 40 hospitals within 15 days of approval [1] - The company is accelerating the global clinical development of its pipeline products, with nine Phase III clinical studies progressing steadily, three of which have received FDA approval [1]

Group 1 - The complexity of hematological tumors presents numerous investment opportunities in various subtypes of treatment [1] - The market for hematological tumors is expanding due to innovative therapies, with significant product launches expected [1] - The number of long-term patients is increasing, with approximately 4 million patients globally having survived five years or more as of 2022, which is three times the number of new patients [1] Group 2 - Future development directions for hematological tumor treatment include improving efficacy, reducing recurrence, and optimizing administration [2] - Acute leukemias like AML and ALL primarily use chemotherapy or targeted combination therapies to enhance survival rates [2] - CAR-T therapy shows high remission rates for aggressive lymphomas and multiple myeloma, providing more treatment options for patients [2] Group 3 - The competition in the targeted drug market for hematological tumors has entered a new phase, with a focus on technological iterations and exploration of new targets [3] - In the BTK field, new products are emerging to compete in the post-resistance market, with Zebutinib outperforming Ibrutinib [3] - The BCL-2 domain is seeing advancements with differentiated designs and optimized dosing strategies to gain competitive advantages [3]

Core Viewpoint - The report from China Galaxy recommends the pharmaceutical industry, highlighting the significant growth potential in the hematological oncology market driven by innovative therapies and the increasing number of long-term patients [1] Group 1: Market Dynamics - The hematological oncology market is expanding due to advancements in precision diagnostics, prognostic stratification, immunotherapy, and targeted therapies, leading to improved survival rates and quality of life for patients [1] - According to WHO, the number of long-term patients with hematological malignancies reached approximately 4 million in 2022, which is three times the number of new patients, indicating a growing market for treatments [1] - The market is expected to see blockbuster products, with global sales of Daratumumab exceeding $10 billion in 2024, and both Ibrutinib and Lenalidomide surpassing $5 billion in sales [1] Group 2: Treatment Trends - Future treatment directions for hematological malignancies focus on improving efficacy, reducing relapse rates, and optimizing administration methods, particularly in acute leukemias and chronic leukemias [2] - In chronic myeloid leukemia (CML), the use of BCR-ABL TKI therapy is being explored to overcome resistance through technological iterations and new targets [2] - CAR-T therapy is providing more treatment options for patients with high relapse rates, particularly in aggressive lymphoma and multiple myeloma [2] Group 3: Competitive Landscape - The targeted drug market for hematological malignancies is entering a new competitive phase, with innovations in BTK inhibitors and BCL-2 inhibitors leading the way [3] - Zebutinib has outperformed Ibrutinib, establishing itself as a leading product in the BTK space, while the market for post-resistance treatments is becoming increasingly competitive [3] - In the BCL-2 space, advancements in dosing and differentiated designs are giving products like Lisocabtagene Maraleucel a competitive edge [3] Group 4: Investment Opportunities - The complexity of hematological malignancies presents numerous investment opportunities, particularly as treatment approaches evolve towards chronic disease management [4] - Companies to watch include BeiGene, which is covering the CLL/SLL indications with a comprehensive product matrix, and Innovent Biologics, which is building a diversified product portfolio centered around Orelabrutinib [4] - Ascentage Pharma is focusing on third-generation BCR-ABL inhibitors and BCL-2 inhibitors to create differentiated competitive advantages [4]

Market Overview - The Hong Kong stock market showed mixed performance, with the Hang Seng Index closing at 25,166 points, up 0.17%, while the Hang Seng Technology Index fell by 0.01% [1][5] - The market turnover decreased to HKD 285.29 billion, with significant net selling from southbound funds amounting to HKD 14.68 billion [1][5] - Notable stock movements included Sunny Optical Technology (2382HK) rising by 9.7% due to a 52.56% year-on-year increase in net profit for the first half of the year [1][5] U.S. Market Insights - The S&P 500 index fell for four consecutive days, influenced by a general decline in technology stocks, while the Dow Jones saw a slight increase of 16 points to 44,938 points [2] - Initial jobless claims in the U.S. for August 9 were reported at 224,000, lower than the previous figure of 227,000, indicating a slight improvement in the labor market [2] Sector Performance - The semiconductor, communication, and artificial intelligence sectors in the Hong Kong market showed renewed activity, with ZTE Corporation (0763HK) rising by 3.8% and accumulating a 10.7% increase for the week [3] - The report emphasizes the investment value of Hong Kong stocks centered on Chinese assets, particularly in technology sectors such as artificial intelligence, robotics, and semiconductors [3] Key Company Updates - Hong Kong Exchanges and Clearing Limited (00388) reported a 39% year-on-year increase in net profit to HKD 8.519 billion for the first half of the year, with a significant rise in trading volumes [9] - The average daily trading amount in the securities market reached HKD 240.2 billion, up 118% year-on-year, indicating robust market activity [9] Investment Recommendations - The report suggests focusing on sectors with strong growth potential, including artificial intelligence, robotics, and new consumer sectors supported by policy initiatives [3][9] - Specific companies to watch include BeiGene (6160HK) and CSPC Pharmaceutical Group (1093HK), which are highlighted for their innovation and market position in the biopharmaceutical industry [9]

Investment Rating - The report maintains a "Buy" rating for the blood cancer drug industry [3][6]. Core Insights - The blood cancer market is expanding due to innovative therapies, with significant advancements in precision diagnosis, prognosis stratification, and targeted therapies such as CAR-T and TCE, leading to improved patient survival and quality of life [5][8]. - The number of patients with blood cancer who have survived for five years or more is approximately 4 million globally, which is three times the number of new patients, indicating a growing market for long-term treatments [5][13]. - The high cost of blood cancer drugs and the emergence of blockbuster products are driving market growth, with several drugs expected to exceed $10 billion in sales by 2024 [5][17]. Summary by Sections 1. Blood Cancer Market Expansion - The proportion of new blood cancer patients is less than 10% of all new cancer cases, with a steady increase in incidence rates [8]. - Blood cancer patients have a long survival period, resulting in a large population of existing patients [13]. - The high cost of blood cancer treatments contributes to the frequent emergence of blockbuster drugs [17]. 2. Clinical Diagnosis and Treatment of Blood Cancer - Blood cancers are classified based on cell origin, differentiation, and affected sites, including leukemia, lymphoma, and multiple myeloma [19][20]. - Treatment for acute leukemia primarily involves chemotherapy or targeted combination therapies to improve survival rates [24]. - Lymphoma treatment varies by subtype, with Rituximab being a cornerstone therapy [23]. - Multiple myeloma treatment focuses on CD38 monoclonal antibodies, with ongoing exploration of solutions for relapsed and refractory cases [23]. 3. Analysis of Popular Targets and Therapies - The BTK field is seeing intense competition, with new products emerging to address resistance issues [5]. - The BCL-2 area is advancing with differentiated designs and optimized dosing strategies [5]. - The BCR-ABL TKI domain is witnessing the introduction of third-generation inhibitors that show superior efficacy [5]. 4. Company Profiles - BeiGene is focusing on a comprehensive product matrix to cover CLL/SLL indications [5]. - Innovent Biologics is building a diversified product portfolio centered around Oubreti [5]. - Ascentage Pharma is developing third-generation BCR-ABL inhibitors and BCL-2 inhibitors to create competitive advantages [5]. - Diligent Pharma is innovating with a globally first high-selectivity JAK1 inhibitor and a dual-target LYN/BTK inhibitor [5]. 5. Investment Recommendations - The blood cancer sector presents numerous investment opportunities due to its complexity and the variety of treatment subfields [5]. - The long survival cycle of blood cancer patients and the high costs of drug treatments indicate a significant market potential [5].

Core Insights - The Hang Seng Healthcare Index (HSHCI) has seen a strong increase of 1.86%, with notable gains from stocks such as Ping An Good Doctor (+7.69%) and Lijun Pharmaceutical (+5.95%) [3] - The Hang Seng Innovation Drug Selection Index (HSSCPB) rose by 2.04%, with Lijun Pharmaceutical and King’s Ray Biotechnology also showing significant increases [5] - Heng Rui Medicine reported a 15.88% increase in revenue to 15.761 billion yuan and a 29.67% increase in net profit to 4.450 billion yuan for the first half of 2025 [7] - The company plans to repurchase A-shares worth 1-2 billion yuan to support employee stock ownership plans [7] Market Performance - The Hang Seng Healthcare ETF (513060) increased by 1.13%, with a recent price of 0.72 yuan and a weekly increase of 1.58% [3] - The Hang Seng Innovation Drug Selection ETF (520690) rose by 1.49%, with a recent price of 1.02 yuan and a weekly increase of 0.80% [5] - The trading volume for the Hang Seng Healthcare ETF was 420 million yuan, with a turnover rate of 5.43% [3] Liquidity and Trading Activity - The Hang Seng Innovation Drug Selection ETF had a trading volume of 18.9759 million yuan, with a turnover rate of 4.81% [6] - The average daily trading volume for the Hang Seng Healthcare ETF over the past month was 2.588 billion yuan, ranking first among comparable funds [3] Company Developments - Heng Rui Medicine's Q2 revenue reached 8.556 billion yuan (+12.53%) and net profit was 2.576 billion yuan (+24.88%), marking record highs for the period [7] - The management of China Biopharmaceutical plans to increase their holdings by 1 million shares, signaling confidence in the sector [8] ETF Performance and Valuation - The Hang Seng Healthcare ETF has seen a net value increase of 54.93% over the past two years, ranking 12th out of 91 QDII equity funds [9] - The ETF's latest price-to-earnings ratio (PE-TTM) is 30.35, indicating it is at a historical low compared to the past three years [11] - The Hang Seng Innovation Drug Selection ETF has a PE-TTM of 29.34, also reflecting a low valuation relative to historical performance [13] Key Holdings - The top ten weighted stocks in the Hang Seng Healthcare Index account for 61.65% of the index, including companies like BeiGene and WuXi Biologics [12] - The top ten weighted stocks in the Hang Seng Innovation Drug Selection Index represent 77.56% of the index, highlighting the concentration in leading biotech firms [13]